Interventions are actions taken by or for individuals to reduce the risk, duration, or severity of adverse health conditions. Interventions may be population-based or personal.
DCP2 and GBD present what we know about which health interventions work for a comprehensive range of diseases, injuries, and disabilities in many different contexts. A large share of the disease burden in low- and middle-income countries is attributable to diseases and conditions for which cost-effective interventions are already known and feasible. Selecting the right intervention for a given disease and context matters a great deal. The tools on this page are designed to aid the task.
DCP2 and GBD demonstrate how decision makers could use cost-effectiveness information in combination with information on disease prevalence and avertable illness to determine which interventions should be extended and which ones should be questioned. If developing countries scale up interventions and extend health care services that are cost-effective, the impact on the disease burden could be substantial.
Download Results (CSV)
|
Download Full Data Set (XLS)
| Condition |
Intervention
|
Intervention type
|
Intervention description |
Intervention setting
|
Objective
|
Target population
|
Cost effectiveness
(US$/DALY)
|
Cost effectiveness estimate
(US$)
|
Cost effectiveness range
(US$/DALY)
|
Number of DALYs averted
(hundreds)
|
Number of deaths averted
(hundreds)
|
Quality of cost-effectiveness analysis evidence
|
|
Parkinson's disease
|
Ayurvedic treatment and levodopa or carbidopa |
Personal |
Levodopa (l-dopa), carbidopa, or ayurvedic therapy for partial relief of symptoms |
Local or district hospital, Referral hospital
|
secondary prevention
|
Adults
|
1,132 |
- |
752-1,512 |
0.13 |
-- |
5 |
|
Epilepsy
|
First-line treatment with phenobarbital |
Personal |
First line treatment with phenobarbital to treat epilepsy patients |
Local or district hospital
|
secondary prevention
|
All ages, Adults, Infants or children, Women of childbearing age, Pregnant women, Adolescents and adults, Mothers and infants
|
89 |
- |
-- |
2.99 |
3.32 |
5 |
|
Parkinson's disease
|
Levodopa or carbidopa and deep brain stimulation |
Personal |
Levodopa or carbidopa and deep brain stimulation |
Local or district hospital, Referral hospital
|
secondary prevention
|
Adults
|
31,114 |
- |
-- |
0.15 |
-- |
5 |
|
Meningitis
|
Neisseria meningitidis vaccine |
Population |
Neisseria meningitidis vaccine for serogroups A, C, Y, Wi35 only; unconjugated polysaccharides given subcutaneously; one dose with repeat three to five years later for those at high risk |
Clinic
|
population-oriented medical intervention
|
Infants or children, Mothers and infants
|
12,632 (SubSaharan Africa) |
- |
-- |
-- |
-- |
5 (SubSaharan Africa) |
|
Epilepsy (refractory)
|
Second-line treatment with phenobarbital and lamotrigine or surgery |
Personal |
Antiepileptic drugs, phenobarbital and lamotrigine, or a combination of phenobarbital and surgery to treat epilepsy patients unresponsive to phenobarbital |
Referral hospital
|
secondary prevention
|
All ages, Adults, Infants or children, Women of childbearing age, Pregnant women, Adolescents and adults, Mothers and infants
|
3,027 |
- |
2,994-3,060 |
0.29 |
0.32 |
5 |
|
Tetanus
|
Tetanus toxoid vaccination, mix of strategies |
Population |
Tetanus toxoid vaccination via a mix of strategies depending on local needs, including fixed facilities, immunization campaigns, mobile delivery, and community outreach |
Clinic, Community
|
population-oriented medical intervention
|
Infants or children, Pregnant women, Mothers and infants
|
1,411 |
- |
-- |
-- |
-- |
5 |
Download Results (CSV)
|
Download Full Data Set (XLS)